Back to Search
Start Over
Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?
- Source :
-
Multiple Sclerosis Journal . Nov2020, Vol. 26 Issue 13, p1700-1707. 8p. - Publication Year :
- 2020
-
Abstract
- Background: Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage. Objective: To investigate the significance of serum FAM19A5 in patients with NMOSD. Methods: We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls. Results: The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5. Conclusion: Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4. [ABSTRACT FROM AUTHOR]
- Subjects :
- *NEUROMYELITIS optica
*BIOMARKERS
*DEMYELINATION
*CENTRAL nervous system
*SERUM
Subjects
Details
- Language :
- English
- ISSN :
- 13524585
- Volume :
- 26
- Issue :
- 13
- Database :
- Academic Search Index
- Journal :
- Multiple Sclerosis Journal
- Publication Type :
- Academic Journal
- Accession number :
- 146628438
- Full Text :
- https://doi.org/10.1177/1352458519885489